FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns biotechnology and medicine area. Way provides introduction of the composition containing an adjuvant and a polypeptide to a mammal, in conditions which induce development of anti-C5-response. The polypeptide contains an own amino-acid segment C5a and a protein, binding with maltose.
EFFECT: creation of bond for treatment of inflammatory conditions.
7 cl, 11 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| HUMAN ANTIBODIES AGAINST SEMAPHORIN 4D | 2018 |
|
RU2776443C2 |
| NEW COMPOSITION AND METHODS FOR THERAPY OF IMMNUNE-ASSOCIATED DISEASES WITH IMMUNITY | 2004 |
|
RU2375078C2 |
| NEW COMPLETELY HUMAN VAP-1 MONOCLONAL ANTIBODIES | 2008 |
|
RU2459832C2 |
| ANTIBODIES TO COMPLEMENT COMPONENT C5 | 2015 |
|
RU2693430C2 |
| POLYPEPTIDES DERIVED FROM TRYPTOPHANYL-TRNA-SYNTHETASE AND USES THEREOF IN CONTROLLING OF VASCULARISATION | 2002 |
|
RU2297425C2 |
| APPLICATION OF COMPLEMENT PATHWAY INHIBITORS FOR TREATMENT OF EYE DISEASES | 2006 |
|
RU2417099C2 |
| NEW LIGAND OF CYTOKINE RECEPTOR ZCYTOR17 | 2003 |
|
RU2490276C2 |
| HETERODIMERIC POLIPEPTIDES IL-17 A/F AND POSSIBILITIES OF THEIR THERAPEUTIC APPLICATION | 2007 |
|
RU2440134C2 |
| ANTAGONISTS OF ALK1 RECEPTOR AND LIGANDS AND THEIR APPLICATION | 2007 |
|
RU2559532C2 |
